NCT05062200

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Chinese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Janssen Pharmaceutical K.K. · Industry
• Sex: All
• Age: 20 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-77242113 after single ascending oral dose administration as an immediate-release (IR) tablet formulation in healthy Japanese participants and after single oral dose administration as an IR tablet formulation in healthy Chinese participants; and as a delayed release (DR) tablet formulation in healthy Japanese participants.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-77242113	JNJ-77242113 will be administered as an oral tablet.
DRUG	Placebo	Matching placebo will be administered as an oral tablet.

Timeline

• Start date: 2021-10-25
• Primary completion: 2022-09-28
• Completion: 2022-09-28
• First posted: 2021-09-30
• Last updated: 2025-02-03

Locations

1 site across 1 country: Japan